Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers and melanoma

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Mai, Phuong L ^a   Chatterjee, Nilanjan ^a   Hartge, Patricia ^a   Tucker, Margaret ^a   Brody, Lawrence ^b   Struewing, Jeffery P ^b   Wacholder, Sholom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; JEW; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; BREAST TUMOR; CARCINOMA; CAUSE OF DEATH; ETHNOLOGY; EUROPE; FAMILIAL CANCER; FOUNDER EFFECT; GENETICS; HETEROZYGOTE; OVARY TUMOR; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE; UNITED STATES;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CAUSE OF DEATH; COHORT STUDIES; DISTRICT OF COLUMBIA; EUROPE; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; JEWS; LIFE EXPECTANCY; MALE; MELANOMA; MORTALITY; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 62849118739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004812     Document Type: Article

References (31)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692-695.
2. Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130.
3. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646.
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689.
5. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271.
6. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408.
7. Brosc MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KI, et al. (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372.
8. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316.
9. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, et al. (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24: 863-871.
10. Tai YC, Domcbek S, Parmigiani G, Chen S (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99: 1811-1814.
11. Thompson D, Easton DF, the Breast Cancer Linkage Consortium (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365.
12. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, et al. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98: 1694-1706.
13. Boulton SJ (2006) Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 34: 633-645.
14. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, et al. (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J Clin Oncol 20: 2520-2529.
15. Byrd LM, Shearon A, Maher ER, Woodward E, Belk R, et al. (2008) Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 1535-1542.
16. Chatterjee N, Hartge P, Wacholder S (2003) Adjustment for competing risk in kin-cohort estimation. Genet Epidmiol 25: 303-313.
17. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, et al. (1998) The kin-cohort study for estimating penetrance. Am J Epidemiol 148: 623-630.
18. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, et al. (1999). Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 91: 259-263.
19. Chatterjee N, Wacholder S (2001) A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics 57: 245-252.
20. Gail MH, Pee D, Benichou J, Carroll R (1999) Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs. Genet Epidemiol 16: 15-39.
21. Moore DF, Chatterjee N, Pee D, Gail MH (2001) Pseudo-likelihood estimates of the cumulative-risk of an autosomal dominant disease from a kin-cohort study. Genet Epidemiol 20: 210-227.
22. Liebens FP, Carly B, Pastijn A, Rozenberg S (2007) Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 43: 238-257.
23. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, et al. (2007) Surveillance for familial breast cancer. Differences in outcome according to BRCA mutation status. Int J Cancer 121: 1017-1020.
24. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, et al. (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357: 115-123.
25. Robson M, Chappuis P, Satagopan J, Wong N, Boyd J, et al. (2004) A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6: R8-R17.
26. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, et al. (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283: 2260-2265.
27. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, et al. (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer. J Clin Oncol 26: 20-25.
28. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with BRCA-associatcd ovarian carcinoma. Cancer 97: 2187-2195.
29. Cao L, Li W, Kim S, Brodie SG, Deng C-X (2003) Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17: 201-213.
30. Dizin E, Gressier C, Magnard C, Ray H, Decimo D, et al. (2006) BRCA1 interacts with Poly(A)-binding protein: implication of BRCA1 in translation regulation. J Biol Chem 281: 24236-24246.
31. Shukla V, Coumoul Y, Cao L, Wang R-H, Xiao C, et al. (2006) Absence of the full-length Breast Cancer-Associated Gene-1 leads to increased expression of Insulin-Like Growth Factor signaling axis members. Cancer Res 66: 7151-7157.